|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 2/09/09 Dnaprint Genomics Inc 8-K:5 1/25/09 1:10K Issuer Direct/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 11K
| UNITED STATES |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
______________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 25, 2009
______________
DNAPrint Genomics, Inc.
(Exact name of registrant as specified in its charter)
______________
Utah | 59-2780520 | |
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
of Incorporation) | File Number) | Identification No.) |
1621 West University Parkway, Sarasota, FL 34243
(Address of Principal Executive Office) (Zip Code)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Employment Termination
Effective as of January 25, 2009 Richard Gabriel, Chief Executive Officer and President and member of the board of directors resigns from all activities at DNAPrint Genomics, Inc. Ellipsis Biotherapeutics Corporation and Trace Genetics, Inc. and their respective boards of directors.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| DNAPrint Genomics, Inc. | |
|
|
|
|
|
|
| By: | /s/ RICHARD GABRIEL |
|
| Richard Gabriel Chief Executive Officer and President |
|
| |
Date: February 9, 2009
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/9/09 | None on these Dates | ||
| For Period End: | 1/25/09 | |||
| List all Filings | ||||